Clene (NASDAQ:CLNN) Given “Buy” Rating at D. Boral Capital

Clene (NASDAQ:CLNN)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $23.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 455.56% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Clene in a research report on Wednesday, March 12th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $55.25.

Clene Stock Performance

NASDAQ CLNN opened at $4.14 on Monday. The company has a market cap of $34.47 million, a PE ratio of -0.78 and a beta of 0.27. The firm’s 50 day moving average price is $4.57 and its 200-day moving average price is $4.92. Clene has a 52-week low of $3.82 and a 52-week high of $9.20.

Institutional Investors Weigh In On Clene

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fullcircle Wealth LLC purchased a new position in Clene in the fourth quarter worth $69,000. SBI Securities Co. Ltd. acquired a new position in Clene during the 4th quarter valued at about $69,000. Renaissance Technologies LLC acquired a new position in Clene during the 4th quarter valued at about $96,000. Parsons Capital Management Inc. RI purchased a new stake in Clene in the fourth quarter valued at about $194,000. Finally, Geode Capital Management LLC boosted its holdings in Clene by 52.9% in the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after acquiring an additional 22,539 shares in the last quarter. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.